Dual PI3K Delta/Gamma Inhibitor, Clinical Trials, TCL

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

This study is ongoing, but not currently recruiting new participants.

The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.

Study Type:  Interventional

Study Design:        

Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title:  A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma


Lymphoma, T-Cell, Peripheral
Lymphoma, T-Cell, Cutaneous                                                      

Intervention:  Drug:  RP6530                                                                              

Phase:  Phase 1

External Link:  https://clinicaltrials.gov/ct2/show/NCT02567656?term=NCT02567656&rank=1